Replimune Stock Explodes as FDA Gives Skin Cancer Drug RP1 a Third Chance!
Replimune stock jumped after FDA gave RP1 melanoma drug another approval chance with fast review and resubmission.
/ 1653 items
#XY↓
Tempus AI Gets FDA Green Light for Simpler Tumor-Only Cancer Test
Tempus AI gets FDA approval for tumor-only cancer DNA test, making diagnosis easier and boosting future revenue potential.
Agios Stops Tebapivat for LR-MDS – But It’s Still Moving Forward for Sickle Cell Disease
Agios scraps LR-MDS drug tebapivat after weak results but continues sickle cell trials; safety was good.
Activist Investor Echo Lake Capital Launches Takeover Bid for Crashing Aclarion Stock
Echo Lake offers $4/share to buy Aclarion, plus profit rights; says company is undervalued and wants reply by June 4, 2026.
Teladoc Health Partners with Walmart to Offer Virtual Doctor Visits
Teladoc Health and Walmart launch cheap virtual care for urgent, skin, and nutrition needs via Walmart app.
TD Cowen & Evercore ISI Praise “Compelling” EDIT-401 Data as Editas Eyes 2026 Human Trials
Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.